Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avenue Therapeutics Inc ATXI

Healthcare Drug Manufacturers - Specialty & Generic
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA a2, a3) receptor positive allosteric modulator for central nervous system (CNS) diseases; and IV tramadol, which is in phase III clinical development for the management of acute postoperative pain in adults in a medically supervised healthcare setting. AJ201 is a pleiotropic small molecule that is designed to modify multiple mechanisms including degradation of the abnormal AR protein and stimulation of Nrf1 and Nrf2, which are involved in protecting cells form oxidative stress which can lead to cell death. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties.


NDAQ:ATXI - Post by User

Avenue Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(98)
•••
Post by whytestockson Apr 29, 2024 5:30pm
27 Views
Post# 36013544

Avenue Therapeutics Announces Exercise of Warrants for $4.4

Avenue Therapeutics Announces Exercise of Warrants for $4.4
Breaking News: $ATXI Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross ProceedsMIAMI, April 29, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (&#x201C;Avenue&#x201D; or the &#x201C;Company&#x201D;), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced th...ATXI - Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities